CARDIOLOGY / CLINICAL RESEARCH
Improvement in age- and sex-dependent mortality in patients with atrial fibrillation between 2011 and 2016 – a nationwide retrospective study from Hungary
More details
Hide details
1
2nd Department of Medicine and Nephrological Centre, Faculty of Medicine, University of Pécs, Pécs, Hungary
2
Bekes County Central Hospital Pandy Kalman Branch, Cardiology Department, Gyula, Hungary
3
Cardiology Department, Hetényi Géza Jász-Nagykun-Szolnok County Hospital, Szolnok, Hungary
4
Heart Centre Balatonfüred and Heart and Vascular Centre, Semmelweis University, Budapest, Hungary
5
RxTarget Ltd., Szolnok, Hungary
6
University of Veterinary Medicine, Budapest, Hungary
7
Eötvös Loránd University, Budapest, Hungary
8
Department of Cardiology, Military Hospital, Budapest, Hungary
9
Department of Cardiology, Petz Aladar County Teaching Hospital, Gyor, Hungary
10
Department of Cardiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
11
Heart and Vascular Centre, Semmelweis University, Budapest, Hungary
Submission date: 2020-09-07
Final revision date: 2020-10-12
Acceptance date: 2020-10-12
Online publication date: 2021-01-11
Publication date: 2026-08-28
Corresponding author
Zoltan Kiss
2nd Department
of Medicine and
Nephrological Centre
Faculty of Medicine
University of Pécs
Pécs, Hungary
1 Pacsirta St
H-7624 Pécs, Hungary
Phone: +36 30 681 7524
Arch Med Sci 2026;22(4):2077-2087
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Atrial fibrillation (AF) is associated with a higher risk of mortality; however, detailed analysis on the excess risk of death of patients diagnosed with AF compared to a non-AF population has not been carried out.
Material and methods:
In our nationwide study, all AF patients were included if the I48 ICD-code was recorded twice in the Hungarian National Health Insurance Fund (NHIF) database between 2009 and 2016. The annual mortality rates and rate ratios of AF patients compared with the non-AF population (excess risk) were evaluated as well as the change of these parameters between 2011 and 2016.
Results:
We identified 88,848 to 123,255 females and 80,525 to 116,448 males between 2011 and 2016 in the database. The excess risk of AF compared to the non-AF population was higher in females: the rate ratio (RR) was 4.47 (95% CI: 4.35–4.58; p < 0.001) versus 3.34 (95% CI: 3.27–3.40; p < 0.001) in 2011. We found significant reductions in the mortality rates of the AF population between 2011 and 2016 (18.0% p = 0.037 in females and 17.7% p < 0.001 in males) while reductions in excess mortality were significant in the older age groups (age 60 years and above). Though the age-specific mortality rates were higher among the older population and in males, mortality RR was higher in the lower age groups and in females.
Conclusions:
By implementing a novel methodology, we were able to express the mortality risk of the total AF population. We found relevant reduction in the age-standardised mortality rates in both sexes during this 6-year period, which exceeded the reduction of mortality rates in the non-AF population.
REFERENCES (34)
1.
Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet 2015; 386: 154-62.
2.
Fitzmaurice DA, Hobbs DR, Jowet S, et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ 2007; 335: 386-91.
3.
Wilke T, Groth A, Mueller S, et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace 2013; 15: 486-93.
4.
Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 271: 840-4.
5.
Goto S, Bhatt DL, Rother J, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J 2008; 156: 855-63.
6.
Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113: 359-64.
7.
Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98: 946-52.
8.
Friberg J, Scharling H, Gadsbøll N, Truelsen T, Jensen GB; Copenhagen City Heart Study. Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). Am J Cardiol 2004; 94: 889-94.
9.
Miyasaka Y, Barnes ME, Bailey KR, et al. Mortality trends in patients diagnosed with first atrial fibrillation a 21-year community-based study. JACC 2007; 49: 986-92.
10.
Piccini JP, Hammill BG, Sinner MF, et al. Incidence and prevalence of atrial fibrillation and associated mortality among medicare beneficiaries: 1993–2007. Circ Cardiovasc Qual Outcomes 2012; 5: 85-93.
11.
European Commission. Revision of the European Standard Population – Report of Eurostat’s task force. Luxembourg: Publications Office of the European Union, 2013.
12.
Altman DG. Practical statistics for medical research. Chapman & Hall, London 1991.
13.
Friberg L, Hammar N, Pettersson H, Rosenqvist M. Increased mortality in paroxysmal atrial fibrillation: report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF). Eur Heart J 2007; 28: 2346-53.
14.
Guize L, Thomas F, Bean K, Benetos A, Pannier B. Atrial fibrillation: prevalence, risk factors and mortality in a large French population with 15 years of follow-up. Bull Acad Natl Med 2007; 191: 791-803.
15.
Potpara T, Grujic M, Marinkovic J, et al. Relationship between mortality of patients with atrial fibrillation and mortality of general population in Serbia. Srp Arh Celok Lek 2010; 138: 177-85.
16.
Lee E, Choi EK, Han KD, et al. Mortality and causes of death in patients with atrial fibrillation: a nationwide population-based study. PLoS One 2018; 13: e0209687.
17.
Vinter N, Huang Q, Fenger-Grøn M, et al. Trends in excess mortality associated with atrial fibrillation over.
18.
45 years (Framingham Heart Study): community based cohort study. BMJ 2020; 370: m2724.
19.
Emdin CA, Wong CX, Hsiao AJ, et al. Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies. BMJ 2016; 532: h7013.
20.
Magnussen C, Niiranen TJ, Ojeda FM, et al. Sex differences and similarities in atrial fibrillation epidemiology, risk factors, and mortality in community cohorts: results from the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe). Circulation 2017; 136: 1588-97.
21.
Hsu JC, Maddox TM, Kennedy K, et al. Aspirin instead of oral anticoagulant prescription in atrial fibrillation patients at risk for stroke J Am Coll Cardiol 2016; 67: 2913-23.
22.
Cowan JC, Wu J, Hall M, Orlowski A, West RM, Gale CP. A 10 year study of hospitalized atrial fibrillation related stroke in England and its association with uptake of oral anticoagulation. Eur Heart J 2018; 39: 2975-83.
23.
Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-62.
24.
Staerk L, Loldrup Fosbøl E, Lip GYH, et al. Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study. Eur Heart J 2017; 38: 907-15.
25.
Gorst-Rasmussen A, Lip GY, Bjerregaard Larsen T. Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care. Pharmacoepidemiol Drug Saf 2016; 25: 1236-44.
26.
Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GY, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2017; 356: j510.
27.
Kotlęga D, Gołąb-Janowska M, Meller A, et al. Beneficial effects of pre-stroke statins use in cardioembolic stroke patients with atrial fibrillation: a hospital-based retrospective analysis. Arch Med Sci 2019; 15: 385-92.
28.
Hindricks G, Potpara T, Dagres N, et al. ESC Scientific Document Group, 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42: 373-498.
29.
Demir GG, Güneş HM, Seker M, et al. Is the presence of left atrial diverticulum associated with recurrence in patients undergoing catheter ablation for atrial fibrillation? Arch Med Sci Atheroscler Dis 2019; 4: e25-31.
30.
Piotrowski R, Zaborska B, Pilichowska-Paszkiet E, Sikora-Frąc M, Baran J, Kułakowski P. RIVAroxaban TWICE daily for lysis of thrombus in the left atrial appendage in patients with non-valvular atrial fibrillation: the RIVA-TWICE study. Arch Med Sci 2019; 16: 289-96.
31.
Negreva MN, Prodanova K, Vitlianova K, Madjova C. Paroxysmal atrial fibrillation: changes in factor VIII and von Willebrand factor impose early hypercoagulability. Arch Med Sci Atheroscler Dis 2020; 5: e140-7.
32.
Garlapati P, Ur Rahman E, Gayam V, et al. Outcomes of oesophageal variceal bleeding among patients with atrial fibrillation: a propensity-matched analysis of a nationwide inpatient sample. Arch Med Sci Atheroscler Dis 2020; 5: 255-62.
33.
Wańkowicz P, Nowacki P, Gołąb-Janowska M. Risk factors for ischemic stroke in patients with non-valvular atrial fibrillation and therapeutic international normalized ratio range. Arch Med Sci 2019; 15: 1217-22.
34.
Bassand JP, Virdone S, Goldhaber SZ, et al. Early risks of death, stroke/systemic embolism, and major bleeding in patients with newly diagnosed atrial fibrillation. Results From the GARFIELD-AF Registry. Circulation 2019; 139: 787-98.